arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

PharmaCyte Biotech, Inc.

PMCB
$0.59 ▲ +0.01 (+1.05%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
64 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

PharmaCyte Biotech, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -6.0%
FCF / Share None
Trailing P/E
Price / Book 0.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-4.39M
↑ +47.4%
FCF / Share Free cash flow per share
$-0.08
↑ +41.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality
28

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 64 quarters